[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1964

Perphenazine (Trilafon) Metabolism in Psychotic Patients

Author Affiliations

Research Department, Spring Grove State Hospital.

Arch Gen Psychiatry. 1964;10(6):639-646. doi:10.1001/archpsyc.1964.01720240093010

Introduction  The discovery that chlorpromazine had marked therapeutic efficacy in the treatment of certain types of psychotic symptomatology stimulated the synthesis and clinical evaluation of many of its prototypes. A number of these have established places for themselves in psychiatric treatment. Comparative clinical studies have indicated differences in their sedative effects, potency (dosage), rapidity of action, and the incidence of neurological complications.1-4The factors responsible for these differences are as yet largely unknown. In the attempts to obtain further insight into these areas, investigations of the metabolism of the individual phenothiazines have been initiated. Chlorpromazine has had the largest amount of study to date.5-12 Despite this, relatively little is known as to its metabolic pathway. Other phenothiazine compounds have also been investigated, but the resultant knowledge is even more limited. Some of these have been levomepromazine,13 promazine,14,15 thioridazine,

First Page Preview View Large
First page PDF preview
First page PDF preview